Sanofi Lines Up for Potential Approval of Cold Agglutinin Disease Treatment
Sanofi Lines Up for Potential Approval of Cold Agglutinin Disease Treatment
SABCS: Pfizer’s Ibrance backs up benefit in HER2-negative breast cancer with real-world data
SABCS: Pfizer’s Ibrance backs up benefit in HER2-negative breast cancer with real-world data
Myeloma cell therapies, now in pharma hands, move into spotlight
Myeloma cell therapies, now in pharma hands, move into spotlight
Ipsen, Enzyvant Hit with Setbacks from the FDA This Week
Ipsen, Enzyvant Hit with Setbacks from the FDA This Week
Πρωταγωνίστρια η ογκολογία στις κλινικές δοκιμές με 598 το 2018
Πρωταγωνίστρια η ογκολογία στις κλινικές δοκιμές με 598 το 2018
After Five Potential Blockbuster Wins This Year, Novartis Sees 25 More on Its Horizon
After Five Potential Blockbuster Wins This Year, Novartis Sees 25 More on Its Horizon
Genentech Earns Another Lung Cancer Approval for Tecentriq
Genentech Earns Another Lung Cancer Approval for Tecentriq
MSD Ελλάδας: 103 φάρμακα, 25 κλινικές μελέτες και ευρύ πρόγραμμα ΕΚΕ
MSD Ελλάδας: 103 φάρμακα, 25 κλινικές μελέτες και ευρύ πρόγραμμα ΕΚΕ
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
Σήμερα το 8th Clinical Research Conference
Σήμερα το 8th Clinical Research Conference
Will Biogen’s Stock Soar or Implode on Alzheimer’s Data?
Will Biogen’s Stock Soar or Implode on Alzheimer’s Data?
Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Astellas Buys Audentes for $3 Billion to Expand into Gene Therapy
Astellas Buys Audentes for $3 Billion to Expand into Gene Therapy
Roche SMA therapy granted speedy FDA review; decision by May 2020
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Dive Brief: The Food and Drug Administration will give Roche’s experimental therapy for spinal muscular atrophy … Continue Reading Roche SMA therapy granted speedy FDA review; decision by May 2020
Πανευρωπαϊκή ελληνική πρωτιά με τα λιγότερα ορφανά φάρμακα και τις χαμηλότερες δαπάνες για σπάνιες παθήσεις
Πανευρωπαϊκή ελληνική πρωτιά με τα λιγότερα ορφανά φάρμακα και τις χαμηλότερες δαπάνες για σπάνιες παθήσεις
Go or no go? Vascepa’s finale and Allergan’s pain relief
Go or no go? Vascepa’s finale and Allergan’s pain relief
